Best Intentions: The Highs and Lows of the Home Affordable ...
THE ‘HIGHS’ AND ‘LOWS’ OF SGLT 2...
Transcript of THE ‘HIGHS’ AND ‘LOWS’ OF SGLT 2...
THE ‘HIGHS’ AND ‘LOWS’ OF SGLT-
2 INHIBITORS
Dr. Chiara Pretto, Dr. Naheed Mirebrahimi and Dr. David
Trachtenbarg
UICOMP
May 2017
A newer Diabetes
Mellitus medication
Sodium-Glucose co-
transport INHIBITOR
Prevents the
reabsorption of the
majority of glucose
filtered by the kidney (Hirsh and Peters) 1
Hypothesis
The HgbA1C reduction in clinical practice is comparable to
the HgbA1C reduction on the SGLT-2 Inhibitor package
inserts
Primary Outcome: To measure the reduction in HgbA1c
after starting SGLT -2 inhibitor therapy in adult patients at
UnityPoint Health
Secondary Outcomes: To measure weight reduction in our
study population
Design: Retrospective observational study though EPIC electronic
medical record
Inclusion: UnityPoint Health male and female diabetic patients greater
than 18 years old prescribed an SGLT-2 inhibitor
Exclusion: Patients initiated on an SGLT2 inhibitor with another DM
medication. Patients start and stop dates for an SGLT-2 inhibitor were
less than 90 days.
Statistical analysis: Paired one-tail and unpaired t-tests were used
for measuring HgbA1C and weight.
Of UnityPoint Health Adults (>18 yo) with Diabetes Mellitus,
6,417 patients were prescribed an SGLT-2 Inhibitor and
used it for 90 days +
Data collected from Spring 2013 to present
Females Males
Number 2774 3643
Average Age 58.3 58.6
RESULTS
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
HgbA1C 8.52% 7.67% 7.65%
Average Days from Baseline -2.9 108 234
HgbA1c change from baseline -0.85 -0.87
n 1078 1078 1078
Significance (Paired T-Test) <0.0001 <0.33 (NS)
7.15
7.43
7.70
7.98
8.25
8.53
Baseline 3 mo 9 mo
Reduction in HgbA1c
All HgbA1Cs While Patients on an SGLT-2
Days from Starting to 2 Years
Data Used for the Preliminary Analysis
Average
HgbA1C Reduction for Different SGLT-2 Medications
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Canagliflozin 8.50% 7.61% 7.60%
Dapagliflozin 8.62% 7.77% 7.73%
Empagliflozin 8.42% 7.71% 7.67%
Significance (Unpaired T-Tests) NS NS NS
4.00
5.50
7.00
8.50
10.00
Baseline 3 mo 9 mo
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Low dose 8.49% 7.66% 7.60%
High dose 8.58% 7.68% 7.67%
Significance by unpaired t-test 0.13 (NS) 0.69 (NS) 0.31(NS)
4.00
5.50
7.00
8.50
10.00
Baseline 3 mo 9 mo
HgbA1C Reduction
Low vs. High dose SGLT-2 Inhibitor Treatment
Change in baseline HgbA1c of -0.85 after 3 months
The 90-149 day reduction is highly significant, but no significant additional reduction between 150 - 360 days
No significant difference between approved SGLT-2 inhibitor medications
No significant difference between high vs. low dose treatments
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Weight (lbs) 243.3 238.3 237.8
Average Days from Baseline -5.1 110 205
n 2355 2355 2355
Significance (Unpaired T-Test) <0.001 <0.37 (NS)
234.50
236.25
238.00
239.75
241.50
243.25
245.00
Baseline 3 mo 9 mo
Weight Reduction
Weight Reduction: Different SGLT-2 Medications
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Wt on Canagliflozin (lbs) 243.8 239.1 238.4
Wt on Dapagliflozin (lbs) 244.2 238.5 238.7
Wt on Empagliflozin (lbs) 239.7 235.1 233.9
Significance (Unpaired T-Tests) NS NS
100.00
137.50
175.00
212.50
250.00
Baseline 3 mo 9 mo
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Low Dose SGLT-2 (lbs) 238.5 233.2 233.3
High Dose SGLT-2 (lbs) 246.6 241.8 240.9
Significance (unpaired t-test) NS NS
100.00
137.50
175.00
212.50
250.00
Baseline 3 mo 9 mo
Weight Reduction: High dose vs. Low dose
Weight after discontinuation of SGLT2 Inhibitor
Baseline
( +/- 1 mo)
3mo
(3-5 mo)
9mo
(6-12 mo)
Weight (lbs) 232.3 233.2 233.9
Average Days from Baseline 7.2 109 194
n 738 738 738
Significance (paired T-Test) 0.76 (NS) <0.8 (NS)
100.00
137.50
175.00
212.50
250.00
Baseline 3 mo 9 mo
Average weight loss of ~5.0 lbs. after 90-149 days for all medications
90-149 day weight reduction is highly significant, but no significant additional reduction between 150 and 360 days
No significant difference in weight loss between the SGLT-2 Inhibitors
No significant weight change after discontinuation of SGLT-2 Inhibitor at 90-149 days or 150-360 days.
INVOKANA Package Insert:
“In patients with type 2 diabetes, treatment with INVOKANA produced clinically
and statistically significant improvements in HgbA1C compared to placebo.” 2
(Janssen Pharmaceuticals, Inc) 2
Invokana
Monotherapy
(26 wks)
Invokana with
Metformin
(26 wks)
Invokana with
Metformin &
Sulfonylurea
(26 wks)
Our study
(after 3 mo)
HgbA1c
(Change
from
baseline)
(-0.77 to -1.42) (-0.79 to -1.78) (-0.85 to -1.06) -0.85
Weight
Reduction
(%)
(-2.8 to -3.9) (-3.7 to -4.2) (-2.1 to -2.6) -2.06
Conclusion
Change in baseline HgbA1c of -0.85 after 3 months
Average weight loss of ~5.0 lbs. after 90-149 days for all medications
highly significant between 90-149 days
No significant difference between approved SGLT-2 inhibitor medications
The HgbA1C reduction in clinical practice is comparable to the
HgbA1C reduction on the SGLT-2 inhibitor package inserts
Patient selection
Patient compliance
Start and Stop dates of SGLT-2 Inhibitor by patient may be
different than Epic dates
Patient may have been prescribed SGLT-2 Inhibitor by
another provider not in Epic
Patients likely on other DM medications prior to SGLT-2
Inhibitor initiation
Lifestyle modifications
A prospective study
Determine the efficacy and side effects in different
ethnicities.
Explore more reasons for discontinuing medication
1. Hirsh, I.B, and Peters, A.L. SGLT-2 Inhibitors and Diabetic Ketoacidosis: What’s all the fuss about? Medscape. http://www.medscape.org/viewarticle/845828_transcript. June 25, 2015. Accessed May 17, 2017.
2. Janssen Pharmaceuticals, Inc. Invokana (Canagliflozin) tablets. https://www.invokana.com/prescribing-information.pdf. February 2017. Accessed May 16, 2017.
Dr. David Trachtenbarg- Research Guidance, Data mining
and Statistical analysis
Dr. Rahmat Na’Allah- Research Guidance
Emily Johnson, UICOMP Librarian & Assistant Professor-
Literature Research
UICOMP IRB